Diabetes drug may be game changer
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sientra collapse doomed execs
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Goleta breast implant maker Sientra shakes up C-Suite
The writing was on the wall at Sientra. On Nov. 12, the company’s top executives took the fall. The embattled Goleta-based breast implant manufacturer cleaned house Thursday afternoon. Sientra founder and CEO Hani Zeini stepped down as CEO and he will be replaced by industry veteran Jeffrey Nugent. Nicholas Simon also resigned as chairman Read More →
Read More →FDA to review Amgen’s new kidney disease dug
Thousand Oaks-based biotech giant Amgen announced on Nov. 6 that the Food and Drug Administration will review a new treatment for patients with chronic kidney disease. The new drug, Etelcalcetide, works by suppressing the secretion of a parathyroid hormone. The drug is administered intravenously three times per week at the end of a dialysis session. Read More →
Read More →Goleta’s Sientra reassures investors, surgeons
This article is only available to Business Times subscribers Subscribers: LOG IN or REGISTER for complete digital access. Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists. Check the STATUS of your Subscription Account.
Read More →Sientra sends letter to surgeons about breast implant production
Sientra CEO Hani Zeini issued a letter to plastic surgeons Oct. 30 outlining what the Goleta-based breast implant manufacturer needs to do to restart production at its plant in Brazil. Zeini also implied in the letter that the Food and Drug Administration is going to make a decision regarding Sientra products, which is something Read More →
Read More →
Sponsored content:
2015-2016 Giving Guide
